Malignant thymoma: current status of classification and multimodality treatment.
Classification, understanding of the pathophysiology, and treatment options of thymoma have changed during recent years. It is hoped that novel strategies will lead to a survival benefit in these patients. It has become clear that patients with thymoma are best treated with multimodality therapy. In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist, and oncologists discuss the current status of classification and strategies for the treatment of patients with thymoma.
Schmidt-Wolf
I G H
IGH
Medizinische Klinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Str. 25, 53105, Bonn, Germany. picasso@uni-bonn.de.
Rockstroh
J K
JK
Medizinische Klinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Str. 25, 53105, Bonn, Germany.
Schüller
H
H
Klinik und Poliklinik für Radiologie, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
Hirner
A
A
Klinik und Poliklinik für Chirurgie, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
Grohe
C
C
Medizinische Klinik und Poliklinik II, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
Müller-Hermelink
H K
HK
Pathologisches Institut der Universität Würzburg, Würzburg, Germany.
Huhn
D
D
Charité, Campus Virchow Klinikum, Klinik für Innere Medizin mit Schwerpunkt Hämatologie-Onkologie, Humboldt-Universität zu Berlin, Berlin, Germany.
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D009367:Neoplasm Staging; D015996:Survival Rate; D013945:Thymoma / Q000145:classification* / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome